The Florence Effect Calls for Nominations!
On Florence Nightingale’s 200th birthday, the legacy of the trailblazing nurse has never been so relevant-as health care workers and researchers across the globe continue to battle against the COVID-19 pandemic.
In an effort to celebrate, honor and connect clinical research workers during this time, Florence Healthcare is calling for nominations of inspiring clinical researcher professionals in an initiative called The Florence Effect. For each nomination, the Florence Effect will make a donation to Greater Gift, and the individual with the most votes will receive a $500 American Express gift card.
Florence hopes this initiative will serve as a platform to appreciate deserving clinical researchers and offer support and encouragement during this challenging time for health care.
You can nominate as many individuals as you’d like, and vote up to 10 times per day.
Get more information here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
